Retatrutide 5mg / 10mg / 15mg / 20mg / 30mg

Buy high-purity Retatrutide in Australia (5mg / 10mg / 15mg / 20mg / 30mg). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About Retatrutide

Retatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R). Optic Labs supplies retatrutide as a high-purity lyophilised powder in 5mg, 10mg, 15mg, 20mg and 30mg vials, packaged for in vitro and preclinical laboratory research.

Each batch is independently HPLC-tested for purity and identity, with certificates of analysis available on request.

Retatrutide is one of the most actively studied compounds in the metabolic and obesity research literature, following published Phase 2 clinical trial data showing substantial reductions in body weight in human study populations. Optic Labs supplies retatrutide for laboratory research only — not for human consumption, clinical use, or any therapeutic application.

Product specifications

• Compound: Retatrutide (LY-3437943)
• CAS number: 2381089-83-2
• Molecular formula: C₂₂₁H₃₄₃N₅₁O₆₁
• Molecular weight: ~4731.5 g/mol
• Mechanism (research context): Triple agonist — GLP-1R + GIP-R + GCG-R
• Form: Lyophilised (freeze-dried) white powder
• Purity: >99% by HPLC
• Available sizes: 5mg, 10mg, 15mg, 20mg, 30mg vials
• Storage: Store unreconstituted vials at 2–8°C; protect from light. Reconstituted solution stored at 2–8°C and used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

Retatrutide was developed as a successor compound to dual incretin agonists (such as tirzepatide), adding glucagon receptor agonism to the GLP-1/GIP profile. Published preclinical and clinical research has examined retatrutide in the context of:

• GLP-1, GIP and glucagon receptor binding, signalling and downstream pathways
• Body composition and adiposity in animal models
• Energy expenditure and thermogenesis (glucagon-receptor contribution)
• Hepatic lipid metabolism and NAFLD/MASH research models
• Glycaemic control and insulin sensitivity in T2D models
• Phase 1 and Phase 2 clinical pharmacokinetic and weight-change studies

For a more detailed research summary with study citations, see our complete retatrutide research guide, our Australian retatrutide guide, our clinical trial side-effects analysis, and our dosing and titration protocol research guide.

Reconstitution and handling

Retatrutide is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use in any laboratory protocol. A 10mg vial reconstituted in 2mL of bacteriostatic water yields a working concentration of 5mg/mL; 1mL yields 10mg/mL.

Larger vial sizes scale proportionally. Exact volumes should be calculated for each protocol — our reconstitution calculator guide walks through the maths. Reconstituted vials should be stored refrigerated at 2–8°C and protected from light.

Comparisons and related research compounds

Retatrutide sits within the broader class of incretin and metabolic peptides. Researchers may also be interested in:

• AOD-9604 — fragment growth-hormone analogue, fat-loss research
• Tesamorelin — GHRH analogue, lipolysis research
• CJC-1295 + Ipamorelin — growth-hormone-releasing research peptide combination
• 5-Amino-1MQ — NNMT inhibitor, metabolic research

For a direct comparison between AOD-9604 and retatrutide research profiles, see our AOD-9604 vs retatrutide article.

Frequently asked questions

Is retatrutide legal in Australia?

Retatrutide is not currently approved by the Therapeutic Goods Administration (TGA) for therapeutic use in Australia — the compound remains in clinical-trial development. Optic Labs supplies retatrutide strictly as a research chemical for in vitro and preclinical laboratory research — not for human consumption, clinical use or any therapeutic application. For a detailed overview, see our guide to peptide legality and TGA compliance in Australia.

What is retatrutide?

Retatrutide (LY-3437943) is a synthetic 39-amino-acid peptide developed as a triple agonist of the GLP-1, GIP and glucagon receptors. In published research it has been investigated for its effects on body composition, glycaemic control, hepatic lipid metabolism and energy expenditure. See our complete research guide for background.

How does retatrutide differ from semaglutide and tirzepatide?

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP agonist. Retatrutide adds a third receptor target — the glucagon receptor — making it a triple agonist. The published research literature suggests glucagon-receptor agonism contributes to energy expenditure effects beyond what is seen with GLP-1 alone or GLP-1 + GIP. Our research guide covers the comparisons.

How is retatrutide supplied?

Optic Labs supplies retatrutide as a lyophilised powder in glass research vials, available in 5mg, 10mg, 15mg, 20mg and 30mg sizes. Each vial is sealed and shipped with a tamper-evident seal. Certificates of analysis showing HPLC purity testing are available on request.

How much bacteriostatic water do I mix with a retatrutide vial?

Reconstitution volume depends on the vial size and the working concentration required by the research protocol. As a starting reference: 10mg in 2mL of bacteriostatic water yields 5mg/mL; 20mg in 2mL yields 10mg/mL. Our reconstitution guide covers the calculations across all vial sizes.

How should reconstituted retatrutide be stored?

Unreconstituted vials should be stored at 2–8°C and protected from light. Once reconstituted, the solution should be refrigerated at 2–8°C and used within approximately 30 days. For full storage protocols, see our peptide storage guide.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease.

Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.